BET Bromodomain Inhibitor ZEN-3694: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving BET Bromodomain Inhibitor ZEN-3694

• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
  NCT05053971 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
  NCT05803382 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
  NCT05111561 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
  NCT05372640 · Phase: Phase 1 · Ages: 12 Years and older · Sex: All (male and female) · 7 locations

Common questions

How many recruiting trials involve BET Bromodomain Inhibitor ZEN-3694?

5 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.